The nation of Zimbabwe has turned down a significant American healthcare agreement worth 367 million US dollars (£272m) spanning five years due to Washington's insistence on confidential biological samples.
The decision became public after a government memo from December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the deal was "skewed".
An official spokesman has since clarified that the United States was requesting biological samples for scientific study and profit but was unwilling to guarantee the resulting advantages from future medical innovations.
"We are forced to start the difficult and regrettable process of ending our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had furnished more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for continued negotiations to secure a agreement acceptable to both sides so the country's critical HIV treatment initiative can proceed.
Broader Implications
This rejection comes after a similar case in Kenya, where a court blocked a similar deal with the US following legal challenges were filed about the security of Kenyans' health data.
Since resuming the presidency recently, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had managed aid for the US government, but Trump claimed its spending was "wasteful" and his administration was pursuing direct bilateral deals to enhance openness and accountability.
As per reports, 16 African countries have to date signed these new health pacts, representing more than $18.3bn in new funding.
Details of the Rejected Agreement
This assistance for Zimbabwe would have supported "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration might have yielded immense benefits for Zimbabwean communities, especially the 1.2 million presently receiving HIV treatment via American-funded initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana said the proposed deal was "unfair".
"Zimbabwe was being asked to share its biological resources and data indefinitely, with no corresponding assurance of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could result from that provided information," his statement read.
"In essence, our country would supply the basic resources for scientific discovery with no assurance that the resulting innovations would be accessible to our population should a new health crisis emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the global health body and its pursuit of bilateral health agreements were upending systems previously established via the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to manage future pandemics.
"This system is intended to guarantee that when a nation provides its samples, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the funds to develop them."
Zimbabwe's reservations over the US deal "are not meant as hostility towards the US," he added.
"We encourage further discussions with our American counterparts on how future co-operation might be structured in a way that honours the sovereignty and interests of each country."
Medical Community Reaction
A leading public health body said it understood the official position, but urged that talks must proceed given that a large portion of the country's Aids initiatives were funded by external financing.
"In cases where technical issues arise, such as those involving data governance or agreement terms, these can frequently be addressed through detailed discussion and mutually agreed protections," the group added.
The situation underscores the complex challenges between accepting crucial foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.